Source:http://linkedlifedata.com/resource/pubmed/id/14532975
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-10-8
|
| pubmed:abstractText |
Virulizin, a novel biological response modifier (BRM), has been demonstrated to have a high level of anti-tumor activity against pancreatic cancer and melanoma in many clinical trials and preclinical studies. However, its anti-tumor mechanism has not been fully elucidated. The purpose of this study was to define the mechanism of Virulizin anti-tumor activity in cultures and in a murine xenograft model. The presence of Virulizin stimulated in a dose-dependent manner the cytolytic activity against tumor cells by splenocytes and macrophages, but not by non-adherent splenocytes. The cytotoxic activity of macrophages was significantly increased (approximately 5-fold) in cultures containing 2.5% of Virulizin compared to that of cultures without Virulizin (p<0.001). An increase of 21% in the protease secretion was observed in Virulizin (2.5%)-stimulated macrophages compared to PBS-treated cells (p<0.0001). Moreover, the anti-tumor efficacy of Virulizin observed in CD-1 nude mice was abrogated in mice that were depleted of macrophages, thus stimulation of macrophages may be one mechanism through which Virulizin acts. These results suggest that macrophages may play a critical role in the anti-tumor activity of Virulizin.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Endopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Extracts,
http://linkedlifedata.com/resource/pubmed/chemical/virulizin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1019-6439
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1341-6
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:14532975-Adjuvants, Immunologic,
pubmed-meshheading:14532975-Animals,
pubmed-meshheading:14532975-Antineoplastic Agents,
pubmed-meshheading:14532975-Bile,
pubmed-meshheading:14532975-Cell Line, Tumor,
pubmed-meshheading:14532975-Dose-Response Relationship, Drug,
pubmed-meshheading:14532975-Endopeptidases,
pubmed-meshheading:14532975-Female,
pubmed-meshheading:14532975-Flow Cytometry,
pubmed-meshheading:14532975-Humans,
pubmed-meshheading:14532975-Macrophages,
pubmed-meshheading:14532975-Melanoma,
pubmed-meshheading:14532975-Mice,
pubmed-meshheading:14532975-Mice, Nude,
pubmed-meshheading:14532975-Neoplasm Transplantation,
pubmed-meshheading:14532975-Pancreatic Neoplasms,
pubmed-meshheading:14532975-Spleen,
pubmed-meshheading:14532975-Time Factors,
pubmed-meshheading:14532975-Tissue Extracts
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Macrophages play a critical role in the anti-tumor activity of Virulizin.
|
| pubmed:affiliation |
R&D Department, Lorus Therapeutics Inc., Toronto, Ontario M9W 4Z7, Canada.
|
| pubmed:publicationType |
Journal Article
|